Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SAFit2是一种高效、具有选择性的fk506结合蛋白51(FKBP51)抑制剂(Ki:6 nM)。SAFit2能增强AKT2-AS160的结合,参与体内糖皮质激素释放的下游反应,是治疗肥胖、慢性疼痛、抑郁和焦虑的候选化合物。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 690 | 现货 | ||
5 mg | ¥ 1,670 | 现货 | ||
10 mg | ¥ 2,490 | 现货 | ||
25 mg | ¥ 4,180 | 现货 | ||
50 mg | ¥ 5,980 | 现货 | ||
100 mg | ¥ 8,250 | 8-10周 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,560 | 现货 |
产品描述 | SAFit2 is a highly effective and selective fk506 binding protein 51(FKBP51) inhibitor (Ki: 6 nM). SAFit2 can enhance AKT2-AS160 binding and participate in the downstream response of glucocorticoid release in vivo, and is a candidate compound for the treatment of obesity, chronic pain, depression and anxiety. |
靶点活性 | FKBP51:6 nM(ki) |
体外活性 | SAFit2 treatment enhances pAKT2 expression in the soleus and EDL muscle, as well as pAS160 expression in the EDL muscle of WT cells, while FKBP51 antagonism has no impact on 51KO cells. Additionally, SAFit2 treatment leads to an increase in membrane-bound GLUT4 expression in primary EDL myotubes from WT mice, whereas no such effect is observed in 51KO mice.[1] |
体内活性 | SAFit2 significantly enhances phosphorylation of AKT2 and AS160 in the EDL muscle, while also increasing GLUT4 expression at the muscle membrane in the soleus. Administration of SAFit2 induces an anxiolytic phenotype in mice tested 16 hours after injection, as evidenced by a significant increase in open arm time in the elevated plus maze (EPM) (z=-2.183, p<0.05). SAFit2 treatment results in a significantly decreased latency to enter the lit compartment (z=-2 to 265, p<0.05), as well as a notable increase in distance, traveled (t(20)=-2.371, p<0.05) within the lit compartment. It has been observed that 30 days of SAFit2 administration leads to reduced body weight in both control and high-fat diet conditions. When SAFit2 is administered 1 hour before testing, no changes in anxiety-related behavior are detected.[1][2] |
分子量 | 802.99 |
分子式 | C46H62N2O10 |
CAS No. | 1643125-33-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (112.1 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.2453 mL | 6.2267 mL | 12.4535 mL | 31.1336 mL |
5 mM | 0.2491 mL | 1.2453 mL | 2.4907 mL | 6.2267 mL | |
10 mM | 0.1245 mL | 0.6227 mL | 1.2453 mL | 3.1134 mL | |
20 mM | 0.0623 mL | 0.3113 mL | 0.6227 mL | 1.5567 mL | |
50 mM | 0.0249 mL | 0.1245 mL | 0.2491 mL | 0.6227 mL | |
100 mM | 0.0125 mL | 0.0623 mL | 0.1245 mL | 0.3113 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SAFit2 1643125-33-0 Apoptosis Autophagy Immunology/Inflammation FKBP SAFit-2 Inhibitor inhibitor inhibit